Cefoxitin: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1040131/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='10/1040131/Cv/1'> | ||
Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. See also [https://en.wikipedia.org/wiki/Cefoxitin Cefoxitin]. | Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. See also [https://en.wikipedia.org/wiki/Cefoxitin Cefoxitin]. | ||
Cefoxitin is a beta-lactam antibiotic which binds to penicillin binding proteins, or transpeptidases. By binding to PBPs, cefoxitin prevents the PBPs from forming the cross-linkages between the peptidoglycan layers that make up the bacterial cell wall, thereby interfering with cell wall synthesis. It is a strong beta-lactamase inducer, as are certain other antibiotics (such as imipenem). However, cefoxitin is a better substrate than imipenem for beta-lactamases. | |||
<scene name='10/1040131/Cv/2'>S. aureus penicillin-binding protein 4 (PBP4) in complex with cefoxitin</scene> ([[7kcx]]). | <scene name='10/1040131/Cv/2'>S. aureus penicillin-binding protein 4 (PBP4) in complex with cefoxitin</scene> ([[7kcx]]). | ||